What sectors does Ascendis Pharma A/S focus on?

Ascendis Pharma A/S focuses on Biotech.

Where is Ascendis Pharma A/S located?

Ascendis Pharma A/S is headquartered in Copenhagen, DK.

Ascendis Pharma A/S

Copenhagen · 3 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Ascendis Pharma A/S

1,127 people in our graph share verified history with the Ascendis Pharma A/S team — schools, employers, funds. One of them is your warm intro.

Ben Robbinsunlockedknows Erik Steffensen · together at Harvard Business School (overlapped)

×5knows the team · via Copenhagen Business School

×2knows the team · via University of Cambridge

×2knows the team · via Oracle

knows the team · via London Business School

knows the team · via DTU - Technical University of Denmark

✨ Fox Verdict

Investment thesis

Ascendis Pharma employs an innovation algorithm to identify unmet medical needs where clinically validated parent drugs align with its TransCon technology platform. The company focuses on building a pipeline of therapeutic candidates primarily in endocrinology rare diseases and oncology, aiming to create therapies that meaningfully improve patient outcomes.

Invests inBiotech Copenhagen Denmark Europe Germany North America San Francisco

Source: firm website, verified Aug 6, 2026.

Copenhagen, CA, DK

Founded

2007

Team · 3 people

from curated & public directories

Albert Cha· Chairman· Palo Altoin

Albert Cha is a Managing Partner on Frazier's Life Sciences team, which he co-leads, and co-manages the Frazier Life Sciences Public Fund; he joined the firm in 2021 with over 25 years of experience investing in biopharmaceutical and medical device companies. He was previously a Managing Partner at Vivo Capital and earlier worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer. He holds B.S. and M.S. degrees in Electrical Engineering from Stanford University and completed the Medical Scientist Training Program at UCLA School of Medicine, earning an M.D. and a Ph.D. in Neuroscience.

a•••@frazierls.comreveal

Erik Steffensen· External Consultant CMC and Combination Products· Copenhagen, Capital Region of Denmark, Denmarkin

Director of R&D, Manufacturing and Quality at Novo Nordisk with over 20 years of leadership experience and degrees from Harvard, IMD, and London Business School.

Jan Møller Mikkelsen· President· San Francisco Bay Areain

Jan Møller Mikkelsen is President and Chief Executive Officer of Ascendis Pharma A/S, which he founded in 2007. The biopharmaceutical company develops therapies using its TransCon technology platform, with a pipeline including three endocrinology rare disease candidates in clinical development and an oncology program. Ascendis has achieved positive Phase 3 results for TransCon hGH and is preparing a Biologics License Application submission.

Frequently asked questions

What sectors does Ascendis Pharma A/S focus on?: Ascendis Pharma A/S focuses on Biotech.
Where is Ascendis Pharma A/S located?: Ascendis Pharma A/S is headquartered in Copenhagen, DK.

Images

Similar investors

8VC

8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.

$100K – $50M

ACT Venture Capital

ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.

$1.1M – $16.2M

Amadeus Capital Partners

Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.

$50K – $12.7M

Andreessen Horowitz

Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.

$500K – $50M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M